Abstract
The search for new compounds active in blood coagulation with different properties to classical anticoagulants, e.g. heparin, has led in the recent years to the development of synthetic low molecular weight peptides, inhibitors of the clotting enzymes (1,2). Among these compounds the benzamidine derivatives and the peptidylarginals have been extensively studied in vitro and in vivo blood coagulation. The effects of a synthetic tripeptide, GYKI 14,451 (Boc-D-Phe-Pro-Arg-H) have been studied in our Laboratory both in vitro on platelets and blood coagulation and in vivo in the experimental animal.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
F. Markwardt, Pharmacological control of blood coagulation by synthetic low molecular weight inhibitors of clotting enzymes. Trends Pharmacol. Sci. 1(6):153 (1980).
F. Markwardt, G. Wagner, J. Stürzebecher and P. Walsmann, Nα-arylsulfonyl-ω-(4-amidinophenyl)-α-aminoalkylcarboxylic acid amines — Novel selective inhibitors of thrombin. Thrombosis Res. 17:425 (1980).
I. Reyers, L. Mussoni, M.B. Donati and G. De Gaetano, Failure of aspirin at different doses to modify experimental thrombosis in rats. Thrombosis Res. 18:669–674 (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Plenum Press, New York
About this chapter
Cite this chapter
Tremoli, E., Colli, S., Paoletti, R. (1984). Gyki 14,451, a Synthetic Tripeptide Inhibitor of Thrombin: “In Vitro” and “In Vivo” Studies. In: Strano, A. (eds) Thrombosis and Cardiovascular Disease. Advances in Experimental Medicine and Biology, vol 164. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8616-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8616-2_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-8618-6
Online ISBN: 978-1-4684-8616-2
eBook Packages: Springer Book Archive